Amphetamine
Central nervous system stimulant
Follow Amphetamine on Notably News to receive short updates to your email — rarely!
We include updates on Attention deficit hyperactivity disorder, Adderall, Lisdexamfetamine, Narcolepsy, Norepinephrine, Phentermine, Nootropic, Phenethylamine, Executive functions, Stimulant psychosis, Performance-enhancing substance, Attention deficit hyperactivity disorder predominantly inattentive, Phenylacetone, CYP2D6, Motivational salience, Monoamine neurotransmitter ... and more.
| 2025 |
Attention deficit hyperactivity disorder
New research revealed significant lifespan reductions for adults with ADHD: men with ADHD lived seven years less than men without ADHD, and women with ADHD had a nine-year shorter lifespan compared to their peers.
|
| 2025 |
Executive functions
An umbrella review and meta-meta-analysis of 133 systematic reviews examined 2,724 randomized controlled trials involving over 258,000 participants, conclusively demonstrating that exercise significantly improves executive function, with the most pronounced effects observed in children, adolescents, and individuals with ADHD.
|
| 2025 | A meta-analytic systematic review of 113 randomized controlled trials demonstrated that stimulant medications significantly improved core ADHD symptoms in adults over a three-month period, with good acceptability compared to other treatments. |
| 2024 |
Attention deficit hyperactivity disorder
A CDC study reports approximately 15.5 million U.S. adults have ADHD, with one-third receiving stimulant drug prescriptions and nearly three-quarters experiencing medication shortage challenges.
|
| 2024 |
Attention deficit hyperactivity disorder
A recent study further substantiated previous research on the relationship between ADHD and hyperfocus, reinforcing the understanding of this phenomenon.
|
| 2024 |
Attention deficit hyperactivity disorder
A systematic review was conducted investigating the diagnostic approaches for ADHD in children under 7 years old, concluding that existing studies have low or insufficient evidence strength.
|
| 2024 |
Attention deficit hyperactivity disorder
A systematic literature review and meta-analysis was commissioned by the Patient-Centered Outcomes Research Institute (PCORI) examining the reliability of ADHD rating scales, finding high internal consistency but poor-to-moderate reliability between different raters.
|
| 2024 | A meta-analytic systematic review reported moderate improvements in quality of life when amphetamine treatment is used for ADHD. |
| February 24 2023 |
Lisdexamfetamine
Patent protection for lisdexamfetamine expired in the United States.
|
| 2022 |
Attention deficit hyperactivity disorder
The three ADHD subtypes are maintained in the DSM-5-TR.
|
| 2022 |
Lisdexamfetamine
Became the 69th most commonly prescribed medication in the United States, with over 9 million prescriptions issued, indicating significant medical adoption and usage.
|
| 2022 |
Lisdexamfetamine
A network meta-analysis found lisdexamfetamine was significantly effective as an antidepressant augmentation for treatment-resistant depression.
|
| 2022 |
Phentermine
Phentermine became the 149th most commonly prescribed medication in the United States, with over 3 million prescriptions issued.
|
| 2022 | Xelstrym, a dextroamphetamine transdermal patch, was first marketed as a new amphetamine delivery method. |
| 2021 |
Attention deficit hyperactivity disorder
Global teams of scientists curate the International Consensus Statement, compiling evidence-based findings about the disorder.
|
| 2021 | The American Academy of Sleep Medicine (AASM) published a clinical practice guideline conditionally recommending dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. |
| 2020 |
Attention deficit hyperactivity disorder
A contradictory study was conducted that did not find a higher frequency of hyperfocus in adults with ADHD, though it reported a positive correlation with self-reported ADHD traits.
|
| 2020 |
Attention deficit hyperactivity disorder
A review was conducted exploring the potential link between ADHD symptoms and creativity, specifically examining divergent thinking and creative achievements. The research found creativity associations with subclinical ADHD symptoms rather than the diagnosed disorder itself.
|
| 2020 |
Attention deficit hyperactivity disorder
Global ADHD prevalence statistics were estimated, showing 139.84 million adults with persistent ADHD and 366.33 million adults with symptomatic ADHD worldwide.
|
| 2020 |
Nootropic
A systematic review raised concerns about potential conflicts of interest in nicotine cognitive effect studies, highlighting that over half of the published studies after 2010 had undisclosed tobacco industry affiliations.
|
| 2019 |
Stimulant psychosis
A systematic review and meta-analysis by Murrie et al. investigated the transition from amphetamine-induced psychosis to schizophrenia, finding a pooled proportion of 22% across 5 studies.
|
| 2019 |
Attention deficit hyperactivity disorder
Another research study continued exploration of hyperfocus, confirming the findings from the 2016 study about increased hyperfocus experiences in individuals with ADHD.
|
| 2019 |
Lisdexamfetamine
A systematic review concluded that lisdexamfetamine was the most effective treatment for adult ADHD, highlighting its significant clinical importance in managing the disorder.
|
| 2019 |
Nootropic
A study found that piracetam supplements sold in the United States were inaccurately labeled, raising concerns about the reliability of racetam nootropic product marketing.
|
| 2019 |
Nootropic
The FDA and FTC jointly issued warnings to manufacturers and consumers about potential advertising fraud and marketing scams related to nootropic supplement products.
|
| 2019 | First amphetamine-metabolizing microbial enzyme (tyramine oxidase) from a strain of E. coli was identified in the human gut, demonstrating the ability to metabolize amphetamine, tyramine, and phenethylamine with similar binding affinity. |
| 2019 | A systematic review and meta-analysis assessed the efficacy of 17 different pharmacotherapies for amphetamine and methamphetamine addiction, finding only low-strength evidence that methylphenidate might reduce self-administration of these substances. |
| April 2019 |
Attention deficit hyperactivity disorder
Psychologists Stephen Faraone and Henrik Larsson published a literature review in Molecular Psychiatry, finding an average heritability estimate of ADHD at 0.74, further confirming the strong genetic influence on the disorder.
|
| 2018 |
Attention deficit hyperactivity disorder
A larger meta-analysis updated the estimated frequency of ADHD among prison inmates to 26.2%.
|
| 2018 |
Narcolepsy
Researchers demonstrated that T-cells stimulated by Pandemrix vaccine were cross-reactive with hypocretin peptides through molecular mimicry, potentially explaining the link between the vaccine and type I narcolepsy.
|
| 2018 |
Lisdexamfetamine
First meta-analysis of randomized controlled trials of lisdexamfetamine for antidepressant augmentation was conducted, finding no significant improvement over placebo in depression rating scales.
|
| 2018 |
Nootropic
Nootropic supplements in the United States were identified as having misleading ingredients and illegal marketing practices.
|
| 2018 | A systematic review and network meta-analysis of 50 trials examined various psychosocial interventions for amphetamine, methamphetamine, and cocaine addiction, finding that combination therapy with contingency management and community reinforcement approach showed the highest efficacy and lowest dropout rates. |
| December 2017 | First study published assessing the interaction between amphetamine and human carbonic anhydrase enzymes, examining eleven carbonic anhydrase enzymes and finding that amphetamine potently activates seven of them, with four highly expressed in the human brain. |
| 2016 |
Attention deficit hyperactivity disorder
A study investigated the occurrence of hyperfocus in individuals with ADHD, finding that those with ADHD diagnoses or self-reported ADHD symptoms experience hyperfocus more often or more acutely.
|
| 2016 | Further reviews reinforced the potential of TAAR1-selective agonists for treating psychostimulant addictions, highlighting the ongoing research into addiction treatment. |
| 2015 |
Attention deficit hyperactivity disorder
A meta-analysis estimated ADHD prevalence among prison inmates at 25.5%.
|
| 2015 |
Attention deficit hyperactivity disorder
A meta-analysis estimated the prevalence of ADHD among prison inmates to be 25.5%.
|
| 2015 |
Lisdexamfetamine
FDA gave tentative approval to generic formulations of lisdexamfetamine.
|
| 2015 | Reviews suggested TAAR1-selective agonists have significant therapeutic potential for treating psychostimulant addictions, though only experimental drugs were known to function as TAAR1-selective agonists. |
| 2015 | A systematic review and meta-analysis of high-quality clinical trials revealed that low therapeutic doses of amphetamine produce modest cognitive improvements in healthy adults, including enhancements in working memory, long-term episodic memory, inhibitory control, and aspects of attention. |
| January 2015 |
Lisdexamfetamine
FDA approved lisdexamfetamine for the treatment of binge eating disorder in adults.
|
| 2014 |
Attention deficit hyperactivity disorder
Keith Conners, an early advocate for ADHD recognition, spoke out against overdiagnosis in a New York Times article. In the same year, a peer-reviewed medical literature review suggested that ADHD is underdiagnosed in adults.
|
| 2014 |
Attention deficit hyperactivity disorder
Keith Conners, an early advocate for ADHD recognition, spoke out against overdiagnosis in a New York Times article.
|
| 2014 |
Nootropic
A systematic review was published noting that low doses of amphetamine improve memory consolidation and recall of information in non-ADHD youth.
|
| 2014 | A systematic review found that low doses of amphetamine improve memory consolidation, leading to improved recall of information. |
| February 2014 |
Lisdexamfetamine
Shire pharmaceutical company announced that late-stage clinical trials found Vyvanse (lisdexamfetamine) was not an effective treatment for depression, leading to discontinuation of development for this medical indication.
|
| 2013 |
Narcolepsy
A review article reported additional but weaker genetic links to narcolepsy, including loci for genes TNFSF4, Cathepsin H, and P2RY11-DNMT1.
|
| 2013 |
Attention deficit hyperactivity disorder
The three ADHD subtypes are maintained in the DSM-5.
|
| 2013 | Global amphetamine overdose deaths estimated at 3,788, with a 95% confidence interval of 3,425-4,145 deaths worldwide. |
|
We are only showing the most recent entries for this topic. |
|
This contents of the box above is based on material from the Wikipedia articles Stimulant psychosis, Narcolepsy, Nootropic, Executive functions, Attention deficit hyperactivity disorder, Phentermine, Lisdexamfetamine & Amphetamine, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.